139 related articles for article (PubMed ID: 11954054)
21. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
22. Conserved aromatic residues as determinants in the folding and assembly of immunoglobulin variable domains.
Campion SR
Mol Immunol; 2016 Feb; 70():63-71. PubMed ID: 26742085
[TBL] [Abstract][Full Text] [Related]
23. Engineering antibodies for stability and efficient folding.
Honegger A
Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
[TBL] [Abstract][Full Text] [Related]
24. Role of the domain-domain interaction in the construction of the antigen combining site. A comparative study by 1H-15N shift correlation NMR spectroscopy of the Fv and Fab fragments of anti-dansyl mouse monoclonal antibody.
Takahashi H; Tamura H; Shimba N; Shimada I; Arata Y
J Mol Biol; 1994 Oct; 243(3):494-503. PubMed ID: 7966275
[TBL] [Abstract][Full Text] [Related]
25. The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.
Masuda K; Sakamoto K; Kojima M; Aburatani T; Ueda T; Ueda H
FEBS J; 2006 May; 273(10):2184-94. PubMed ID: 16649995
[TBL] [Abstract][Full Text] [Related]
26. Analysis and prediction of VH/VL packing in antibodies.
Abhinandan KR; Martin AC
Protein Eng Des Sel; 2010 Sep; 23(9):689-97. PubMed ID: 20591902
[TBL] [Abstract][Full Text] [Related]
27. Carrier-specificity of a phosphorylcholine-binding antibody requires the presence of the constant domains and is not dependent on the unique VH49 glycine or VH30 threonine residues.
Tam FC; Ma CH; Leung DT; Sutton B; Lim PL
J Immunol Methods; 2007 Apr; 321(1-2):152-63. PubMed ID: 17331532
[TBL] [Abstract][Full Text] [Related]
28. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
Narayanan A; Sellers BD; Jacobson MP
J Mol Biol; 2009 May; 388(5):941-53. PubMed ID: 19324053
[TBL] [Abstract][Full Text] [Related]
29. Antibody recognition of a flexible epitope at the DNA binding site of the human papillomavirus transcriptional regulator E2.
Cerutti ML; Ferreiro DU; Sanguineti S; Goldbaum FA; de Prat-Gay G
Biochemistry; 2006 Dec; 45(51):15520-8. PubMed ID: 17176073
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of a human VH: requirements for maintaining a monomeric fragment.
Dottorini T; Vaughan CK; Walsh MA; LoSurdo P; Sollazzo M
Biochemistry; 2004 Jan; 43(3):622-8. PubMed ID: 14730966
[TBL] [Abstract][Full Text] [Related]
31. Site-specific photobiotinylation of antibodies, light chains, and immunoglobulin fragments.
Pavlinkova G; Lou D; Kohler H
Methods; 2000 Sep; 22(1):44-8. PubMed ID: 11020316
[TBL] [Abstract][Full Text] [Related]
32. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus.
Zhang M; Zharikova D; Mozdzanowska K; Otvos L; Gerhard W
Mol Immunol; 2006 Jul; 43(14):2195-206. PubMed ID: 16472860
[TBL] [Abstract][Full Text] [Related]
33. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies.
Kim SH; Schindler DG; Lindner AB; Tawfik DS; Eshhar Z
Mol Immunol; 1997; 34(12-13):891-906. PubMed ID: 9464525
[TBL] [Abstract][Full Text] [Related]
34. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies.
Acierno JP; Braden BC; Klinke S; Goldbaum FA; Cauerhff A
J Mol Biol; 2007 Nov; 374(1):130-46. PubMed ID: 17916365
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of a sequence-specific ssDNA binding lupus autoantibody.
Cleary J; Glick GD
Biochemistry; 2003 Jan; 42(1):30-41. PubMed ID: 12515537
[TBL] [Abstract][Full Text] [Related]
36. Conserved amino acid networks involved in antibody variable domain interactions.
Wang N; Smith WF; Miller BR; Aivazian D; Lugovskoy AA; Reff ME; Glaser SM; Croner LJ; Demarest SJ
Proteins; 2009 Jul; 76(1):99-114. PubMed ID: 19089973
[TBL] [Abstract][Full Text] [Related]
37. Cytoplasmic expression and specific binding of the VH/VL single domain intrabodies in transfected NIH3T3 cells.
Sawahata R; Sato M; Kitani H
Exp Mol Pathol; 2009 Feb; 86(1):51-6. PubMed ID: 19094983
[TBL] [Abstract][Full Text] [Related]
38. Mapping the major interaction between binding protein and Ig light chains to sites within the variable domain.
Davis DP; Khurana R; Meredith S; Stevens FJ; Argon Y
J Immunol; 1999 Oct; 163(7):3842-50. PubMed ID: 10490983
[TBL] [Abstract][Full Text] [Related]
39. Binders based on dimerised immunoglobulin VH domains.
Sepúlveda J; Jin H; Sblattero D; Bradbury A; Burrone OR
J Mol Biol; 2003 Oct; 333(2):355-65. PubMed ID: 14529622
[TBL] [Abstract][Full Text] [Related]
40. Comparative interaction kinetics of two recombinant Fabs and of the corresponding antibodies directed to the coat protein of tobacco mosaic virus.
Chatellier J; Rauffer-Bruyère N; Van Regenmortel MH; Altschuh D; Weiss E
J Mol Recognit; 1996; 9(1):39-51. PubMed ID: 8723318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
